相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Care Patterns and Overall Survival in Patients With Early-Onset Metastatic Colorectal Cancer
Katie Kanter et al.
JCO ONCOLOGY PRACTICE (2021)
The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer
Gianluca Mauri et al.
CANCERS (2021)
Colon Cancer, Version 2.2021
Al B. Benson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
Salvatore Siena et al.
LANCET ONCOLOGY (2021)
Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids
Gianluca Mauri et al.
JCO PRECISION ONCOLOGY (2021)
The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer
Giuseppe Nicolo Fanelli et al.
CANCER CELL INTERNATIONAL (2020)
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin
Sabrina Arena et al.
CLINICAL CANCER RESEARCH (2020)
Emotional distress and quality of life during folinic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy A cross-sectional study
Hsin-Tien Hsu et al.
MEDICINE (2020)
Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis
Lauren C. Bylsma et al.
CANCER MEDICINE (2020)
Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study)
Masahito Kotaka et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
G. Argiles et al.
ANNALS OF ONCOLOGY (2020)
The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer
G. Mauri et al.
ANNALS OF ONCOLOGY (2020)
Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer
Chiara Cremolini et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities
Gianluca Mauri et al.
CANCER TREATMENT REVIEWS (2020)
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
T. Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
FOLFOX rechallenge versus regorafenib in patients with metastatic colorectal cancer refractory to standard chemotherapy: A retrospective analysis.
Maria Alessandra Calegari et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
N. Colombo et al.
ANNALS OF ONCOLOGY (2019)
Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer
Sara Bouberhan et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
S. Kopetz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy
L. M. Soveri et al.
ACTA ONCOLOGICA (2019)
Early-onset colorectal cancer in young individuals
Gianluca Mauri et al.
MOLECULAR ONCOLOGY (2019)
Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review
D. Arnold et al.
ANNALS OF ONCOLOGY (2018)
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
S. Siena et al.
ANNALS OF ONCOLOGY (2018)
Oxaliplatin rechallenge in metastatic colorectal cancer patients after prior oxaliplatin treatment
Jae-Joon Kim et al.
MEDICAL ONCOLOGY (2018)
Toxicity of oxaliplatin rechallenge in metastatic colorectal cancer
G. Mauri et al.
ANNALS OF ONCOLOGY (2018)
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
T. Yoshino et al.
ANNALS OF ONCOLOGY (2018)
Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study)
Chu Matsuda et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2016)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study
Katia Bencardino et al.
CLINICAL COLORECTAL CANCER (2016)
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore-Bianchi et al.
LANCET ONCOLOGY (2016)
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
Emanuele Valtorta et al.
MODERN PATHOLOGY (2015)
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
THE MEANING OF ACOMBINATION USE OF BEVACIZUMAB IN REINTRODUCTION OF OXALIPLATIN FOR METASTATIC COLORECTAL CANCER
Ken Nishimura et al.
ANNALS OF ONCOLOGY (2014)
Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2014)
FOLFIRINOX Bevacizumab Is a Promising Therapy for Chemorefractory Metastatic Colorectal Cancer
Marie Chaix et al.
ONCOLOGY (2014)
Platinum-sensitivity in metastatic colorectal cancer: Towards a definition
Benoist Chibaudel et al.
EUROPEAN JOURNAL OF CANCER (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Oxaliplatin-Induced Neuropathy in Colorectal Cancer
Andrew Weickhardt et al.
JOURNAL OF ONCOLOGY (2011)
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
Astrid Lievre et al.
BMC CANCER (2009)
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
T Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
分享论文
